Colon-Targeted Trans-Cinnamic Acid Ameliorates Rat Colitis by Activating GPR109A
Open Access
- 22 December 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 41
Abstract
We designed colon-targeted trans-cinnamic acid (tCA) and synthesized its conjugates with glutamic acid (tCA-GA) and aspartic acid (tCA-AA). We evaluated the anti-colitic activity of colon-targeted tCA using a dinitrobenzenesulfonic acid-induced rat colitis model. The conjugates lowered the distribution coefficient and Caco-2 cell permeability of tCA and converted to tCA in the cecum, with higher rates and percentages with tCA-GA than with tCA-AA. Following oral gavage, tCA-GA delivered a higher amount of tCA to the cecum and exhibited better anti-colitic effects than tCA and sulfasalazine (SSZ), which is the current treatment for inflammatory bowel disease. In the cellular assay, tCA acted as a full agonist of GPR109A (EC50: 530 µM). The anti-colitic effects of tCA-GA were significantly compromised by the co-administration of the GPR109A antagonist, mepenzolate. Collectively, colon-targeted tCA potentiated the anti-colitic activity of tCA by effectively activating GPR109A in the inflamed colon, enabling tCA to elicit therapeutic superiority over SSZ.Keywords
Funding Information
- National Research Foundation of Korea (2021R1I1A3A0403710411)
This publication has 35 references indexed in Scilit:
- A Review on Anti-Inflammatory Activity of Phenylpropanoids Found in Essential OilsMolecules, 2014
- Optimization of conventional therapy in patients with IBDNature Reviews Gastroenterology & Hepatology, 2011
- What should be considered on design of a colon-specific prodrug?Expert Opinion on Drug Delivery, 2010
- GPR109A Is a G-protein–Coupled Receptor for the Bacterial Fermentation Product Butyrate and Functions as a Tumor Suppressor in ColonCancer Research, 2009
- Unravelling the pathogenesis of inflammatory bowel diseaseNature, 2007
- Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitisGut, 2006
- Metabolic and Pharmacological Properties of Rutin, a Dietary Quercetin Glycoside, for Treatment of Inflammatory Bowel DiseasePharmaceutical Research, 2005
- Medical treatment of mild to moderately active Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2003
- Colon-specific delivery of prednisolone-appended α-cyclodextrin conjugate: alleviation of systemic side effect after oral administrationJournal of Controlled Release, 2002
- Drug therapy of ulcerative colitis.British Journal of Clinical Pharmacology, 1992